+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Catechol O-methyltransferase and monoamine oxidase A genotypes, and plasma catecholamine metabolites in bipolar and schizophrenic patients

Catechol O-methyltransferase and monoamine oxidase A genotypes, and plasma catecholamine metabolites in bipolar and schizophrenic patients

Neurochemistry International 56(6-7): 774-779

Metabolites of dopamine and norepinephrine measured in the plasma have long been associated with symptomatic severity and response to treatment in schizophrenic, bipolar and other psychiatric patients. Plasma concentrations of catecholamine metabolites are genetically regulated. The genes encoding enzymes that are involved in the synthesis and degradation of these monoamines are candidate targets for this genetic regulation. We have studied the relationship between the Val158Met polymorphism in catechol O-methyltransferase gene, variable tandem repeat polymorphisms in the monoamine oxidase A gene promoter, and plasma concentrations of 3-methoxy-4-hydroxyphenylglycol, 3,4-dihydroxyphenylacetic acid and homovanillic acid in healthy control subjects as well as in untreated schizophrenic and bipolar patients. We found that the Val158Met substitution in catechol O-methyltransferase gene influences the plasma concentrations of homovanillic and 3,4-dihydroxyphenylacetic acids. Although higher concentrations of plasma homovanillic acid were found in the high-activity ValVal genotype, this mutation did not affect the plasma concentration of 3-methoxy-4-hydroxyphenylglycol. 3,4-dihydroxyphenylacetic acid concentrations were higher in the low-activity MetMet genotype. Interestingly, plasma values 3-methoxy-4-hydroxyphenylglycol were greater in schizophrenic patients and in bipolar patients than in healthy controls. Our results are compatible with the previously reported effect of the Val158Met polymorphism on catechol O-methyltransferase enzymatic activity. Thus, our results suggest that this polymorphism, alone or associated with other polymorphisms, could have an important role in the genetic control of monoamine concentration and its metabolites.

Please choose payment method:

(PDF emailed within 0-6 h: $19.90)

Accession: 051971345

Download citation: RISBibTeXText

PMID: 20206656

DOI: 10.1016/j.neuint.2010.02.015

Related references

Norepinephrine metabolites in plasma as indicators of pharmacological inhibition of monoamine oxidase and catechol O-methyltransferase. Advances in Pharmacology 42: 367-370, 1998

Influence of the catechol-O-methyltransferase Val108/158Met polymorphism on the plasma concentration of catecholamine metabolites and on clinical features in type I bipolar disorder--a preliminary report. Journal of Affective Disorders 92(2-3): 277-281, 2006

Catechol-o-methyltransferase and plasma monoamine oxidase in patients with affective disorders. Acta Psychiatrica Scandinavica. Supplementum 255: 187-192, 1974

Catechol-O-methyltransferase and monoamine oxidase A genotypes and drug response to conventional neuroleptics in schizophrenia. Journal of Clinical Psychopharmacology 23(5): 429-434, 2003

Simultaneous inhibition of catechol-O-methyltransferase and monoamine oxidase A: effects on hemodynamics and catecholamine metabolism in healthy volunteers. Clinical Pharmacology and Therapeutics 59(4): 450-457, 1996

Prolactin levels in schizophrenia: relation to platelet monoamine oxidase, plasma amine oxidase, plasma dopamine-beta-hydroxylase, and erythrocyte catechol-O-methyltransferase activity. Biological Psychiatry 18(5): 579-582, 1983

Effects of long-term administration of pyrogallol on tissue catecholamine levels, monoamine oxidase and catechol-O-methyltransferase activities in the rat. Biochemical Pharmacology 15(12): 1935-1946, 1966

COMT haplotypes, catecholamine metabolites in plasma and clinical response in schizophrenic and bipolar patients. Pharmacogenomics 17(8): 837-851, 2016

Effect of chronic administration of pyrogallol on the activities of catechol-O-methyltransferase and monoamine oxidase and on the urinary metabolites of catecholamin. Folia Pharmacol Japon 58(3): 21, 1962

Detection Of Monoamine Oxidase Activity And Catechol O-Methyltransferase In The Plasma Of Rats Poisoned With Carbon Tetrachloride. Annales de Biologie Clinique 22: 1055-1065, 1964

The contribution by monoamine oxidase and catechol-O-methyltransferase to the total-body and pulmonary plasma clearance of catecholamines. Naunyn-Schmiedeberg's Archives of Pharmacology 353(2): 193-199, 1996

Hydrogen peroxide (H2O2) production by monoamine oxidase in rat tissues using endogenous catecholamines as substrates. A comparison of catalytic monoamine oxidase histochemistry and recently published catechol-O-methyltransferase immunohistochemistry. Acta Histochemica 97(1): 121-127, 1995

Effect of high single doses of levodopa and carbidopa on brain dopamine and its metabolites: modulation by selective inhibitors of monoamine oxidase and/or catechol-O-methyltransferase in the male rat. Naunyn-Schmiedeberg's Archives of Pharmacology 344(4): 412-418, 1991

Distribution of catechol-O-methyltransferase, histamine N-methyltransferase and monoamine oxidase in specific areas of the rat brain. Brain Research 118(1): 152-156, 1976

Polymorphisms of catechol-O-methyltransferase and monoamine oxidase B genes among Chinese patients with Parkinson's disease. Zhonghua Yi Xue Yi Chuan Xue Za Zhi 32(1): 1-5, 2015